Figure 4

Effects of rosiglitazone on anxiety-related behaviors in wild-type and Adipo^−/− mice. (a) Upper, elevated plus-maze test performed 1 h after a single rosiglitazone injection (1 ×, 1 h) in wild-type (WT) mice (Upper-left: percentage of open arm entries; t₍₁₈₎=0.192, P>0.05; upper-middle: percentage of open arm time; t₍₁₈₎=0.480, P>0.05; upper-right: total arm entries; t₍₁₈₎=0.3369, P>0.05). n=10 per group. Middle, elevated plus-maze test performed in WT mice following three rosiglitazone injections within 24 h (3 ×, 24 h). Middle-left: percentage of open arm entries; t₍₁₄₎=2.837, P<0.05. Middle-middle: percentage of open arm time; t₍₁₄₎=3.044, P<0.01. Middle-right: total arm entries; t₍₁₄₎=1.348, P>0.05. n=8 per group. Lower, elevated plus-maze test performed in Adipo^−/− mice following three rosiglitazone injections within 24 h (3 ×, 24 h). Lower-left: percentage of open arm entries; t₍₁₈₎=0.0719, P>0.05. Lower-middle: percentage of open arm time; t₍₁₈₎=0.0116, P>0.05. Lower-right: total arm entries; t₍₁₈₎=0.5084, P>0.05. n=10 per group. (b) Novelty-suppressed feeding test following three rosiglitazone injections within 24 h in WT mice and Adipo^−/− mice. Left, latency to feed of WT mice (t₍₁₄₎=2.915, P<0.05). Middle-left, home-cage food consumption of WT mice (t₍₁₄₎=0.8228, P>0.05). n=8 per group. Middle-right, latency to feed of Adipo^−/− mice (t₍₁₄₎=0.0466, P>0.05). Right, home-cage food consumption of Adipo^−/− mice (t₍₁₄₎=0.799, P>0.05). n=8 per group. *P<0.05, **P<0.01 compared with the saline-treated group. Data are shown as mean±s.e.m.

PowerPoint slide